Home

Editas Medicine, Inc. - Common Stock (EDIT)

3.0300
+0.00 (0.00%)
NASDAQ · Last Trade: Aug 18th, 8:25 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Why Editas Medicine Stock Was Skyrocketing This Weekfool.com
The company's CEO made quite the encouraging statement regarding its immediate future.
Via The Motley Fool · August 15, 2025
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · August 13, 2025
Top movers in Wednesday's sessionchartmill.com
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · August 13, 2025
Wednesday's session: gap up and gap down stockschartmill.com
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Via Chartmill · August 13, 2025
Earnings Scheduled For May 12, 2025benzinga.com
Via Benzinga · May 12, 2025
Peering Into Editas Medicine's Recent Short Interestbenzinga.com
Via Benzinga · February 25, 2025
Editas Medicine Inc (NASDAQ:EDIT) Reports Mixed Q2 2025 Earnings: Revenue Beat but Wider Losschartmill.com
Editas Medicine posted Q2 2025 revenue of $3.58M, beating estimates, but EPS loss widened to -$0.63. Stock dipped 1.75% amid restructuring concerns. Pipeline progress includes IND filing plans for 2026.
Via Chartmill · August 12, 2025
Can This Beaten-Down Stock Bounce Back?fool.com
This small-cap biotech is seeking to develop breakthrough therapies, but so far it's found little success.
Via The Motley Fool · August 12, 2025
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?fool.com
Via The Motley Fool · June 28, 2025
2 Beaten-Down Stocks to Avoidfool.com
Via The Motley Fool · June 27, 2025
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analystbenzinga.com
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.
Via Benzinga · June 18, 2025
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.fool.com
Via The Motley Fool · June 17, 2025
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeoverinvestors.com
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.
Via Investor's Business Daily · June 17, 2025
1 Stock Down 97% That Could Double, According to Wall Streetfool.com
Via The Motley Fool · May 25, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · May 21, 2025
Editas Medicine: A Cautionary Tale for Investorsfool.com
Via The Motley Fool · May 15, 2025
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we will witness groundbreaking changes that redefine how care is delivered, diseases are treated, and wellness is maintained. Below, we explore ten
Via MarketMinute · March 27, 2025
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potentialstocktwits.com
The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027.
Via Stocktwits · March 5, 2025
What's going on in today's sessionchartmill.com
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · February 20, 2025
Earnings Scheduled For March 5, 2025benzinga.com
Via Benzinga · March 5, 2025
Top movers in Thursday's sessionchartmill.com
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · February 20, 2025
Stay updated with the stocks that are on the move in today's pre-market session.chartmill.com
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · February 20, 2025
Top movers analysis one hour before the close of the markets on 2025-02-19: top gainers and losers in today's session.chartmill.com
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Via Chartmill · February 19, 2025
Here are the top movers in Wednesday's session.chartmill.com
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · February 19, 2025
JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Cautionbenzinga.com
Editas Medicine pivots to in vivo gene editing, extends cash runway to 2027, but faces investor caution amid unclear proof-of-concept timelines.
Via Benzinga · December 17, 2024